RECOVER-SLEEP: Platform Protocol

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. ≥ 18 years of age at the time of enrollment

2. Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by thePan American Health Organization: Suspected* case of SARS-CoV-2 infection - Three options, A through C: A. Met the clinical OR epidemiological criteria:

3. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) ORAcute onset of ANY THREE OR MORE of the following signs or symptoms: fever,cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza,dyspnea, nausea, diarrhea, anorexia;

4. Epidemiological criteria: Contact of a probable or confirmed case or linked toa COVID-19 cluster; or B. Presented with acute respiratory infection with ahistory of fever or measured fever of ≥ 38°C and cough, with onset within thelast 10 days, and required hospitalization; or C. Presented with no clinicalsigns or symptoms, NOR meeting epidemiologic criteria with a positiveprofessional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test. Probable* case of SARS-CoV-2 infection, defined as having met the clinical criteriaabove AND was a contact of a probable or confirmed case or is linked to a COVID-19cluster; or Confirmed case of SARS-CoV-2 infection - Two options, A through B: A. Presented with a positive nucleic acid amplification test, regardless of clinicalcriteria OR epidemiological criteria; or B. Met clinical criteria AND/ORepidemiological criteria (See suspected case A), with a positive professional use orself-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.

• Suspected and probable cases will only be allowed if they occurred before May 1, 2021, and will be limited to 10% of the study population. Otherwise, confirmed casesare required.

3. New/worse sleep problems following a SARS-CoV-2 infection that have persisted for atleast 12 weeks and are still present at the time of consent

4. PROMIS 8a SRI or 8b SD T Score ≥ 55**

** Screening with both the PROMIS 8a SRI and 8b SD will occur for the phenotypeassessment portion of the protocol.

5. Willing and able to provide informed consent, complete the surveys and clinicalassessments, and return for all of the necessary follow-up visits

6. Adequate method of birth control for participants of child-bearing potential

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Known active acute SARS-CoV-2 infection ≤ 4 weeks from consent

2. Known pregnancy, breastfeeding, or contemplating pregnancy during the study period

3. Untreated sleep apnea (AHI ≥ 15 or severe sleep-related hypoxemia)

4. Current night or rotating shift work

5. Known history of narcolepsy prior to SARS-CoV-2 infection

6. Any non-marijuana illicit drug use within 30 days of informed consent

7. Known history of severe mental disorder, such as psychotic disorders and bipolardisorder

8. Current or recent use (within the last 14 days) of study intervention or similarintervention to treat the underlying condition, unless a washout period is permittedper appendix*

9. Known allergy/sensitivity or any hypersensitivity to components of the studyintervention or control*

10. Known contraindication(s) to study intervention including prohibited concomitantmedications and without the ability to safely hold prohibited concomitantmedications (see appendices)*

11. Currently receiving/using intervention from another clinical trial that could impactor mask treatment effect; refer to MOP for details

12. Any condition that would make the participant, in the opinion of the investigator,unsuitable for the study

(*)If only one study intervention appendix is open at the time of enrollment. If multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity yet remain eligible for the remaining study intervention appendices.